

# BMJ Open

## Glycemic control efficacy of oral anti-diabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006139
Article Type:	Protocol
Date Submitted by the Author:	17-Jul-2014
Complete List of Authors:	Leung, Siu-wai; University of Edinburgh, School of Informatics; University of Macau, Institute of Chinese Medical Sciences Jia, Yongliang; University of Macau, Institute of Chinese Medical Sciences Lao, Yaoguang; University of Macau, Institute of Chinese Medical Sciences
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Evidence based practice, Health informatics, Pharmacology and therapeutics
Keywords:	Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, General diabetes < DIABETES & ENDOCRINOLOGY, Diabetes & endocrinology < INTERNAL MEDICINE

SCHOLARONE™  
Manuscripts

Glycemic control efficacy of oral anti-diabetic drugs in treating type 2 diabetes:  
a protocol for network meta-analysis

Yongliang Jia<sup>1</sup>, Yaoguang Lao<sup>1</sup>, Siu-wai Leung<sup>1,2\*</sup>

Affiliations:

1. State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China
2. School of Informatics, University of Edinburgh, Edinburgh EH8 9AB, United Kingdom

Email addresses:

YJ: [gentrany@gmail.com](mailto:gentrany@gmail.com)

YL: [yaoguangleo@163.com](mailto:yaoguangleo@163.com)

SL: [swleung@umac.mo](mailto:swleung@umac.mo)

Phone: +853-8397-8524

\*Corresponding author

Keywords: protocol; type 2 diabetes; glycemic control; randomized controlled trials; network meta-analysis.

Word count: 1619

**Abstract****Introduction:**

There were three network meta-analyses on the efficacy of anti-diabetic drug combinations in treating type 2 diabetes. No network meta-analytic study has been published in medical journal to evaluate the efficacies of monotherapy. Current clinical guidelines (e.g. NICE clinical guidelines 66 and 87) are only based on the findings of limited clinical trials and pairwise meta-analysis. This study aims to fill this gap of research by conducting a Bayesian network meta-analysis to compare twelve anti-diabetic drugs, including metformin, pioglitazone, rosiglitazone, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin and acarbose.

**Methods and analyses:**

Randomized controlled trials (RCT) on the drug therapy of type 2 diabetes with outcome measures including glycosylated hemoglobin (HbA1c) or fasting blood-glucose (FPG) will be included. The quality of included RTCs will be evaluated according to the Cochrane Collaboration's risk of bias tool. Overall effect sizes will be represented as mean differences with 95% credible intervals (CrI) for continuous outcome data. Pairwise meta-analysis in R software and Bayesian network meta-analysis in R and WinBUGS will be conducted to compare the efficacies of these drugs. Sensitivity analysis on the sample size of RCTs, contradiction analysis between pair and network meta-analyses, and publication bias analysis will be performed.

**Ethics and dissemination:**

Ethical approval is not required because this study include no confidential personal data and interventions on the patients. Network meta-analysis is based on the RCT reports of eligible drugs in treating type 2 diabetes. The results of this study will be disseminated by an open access and peer-reviewed publication.

**Protocol registration:**

PROSPERO CRD42014010567.

## ARTICLE SUMMARY

## Article focus

- This is a protocol of systematic review and network meta-analysis of randomized controlled trials on metformin, pioglitazone, rosiglitazone, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin and acarbose in treating type 2 diabetes.

## Key messages

- Included drugs will be evaluated by pairwise and a Bayesian network meta-analysis.
- Sensitivity analysis, contradiction analysis, and publication bias analysis will be conducted to compare the efficacy of drugs with glycosylated hemoglobin and fasting blood-glucose outcome measures.

## Strengths and limitations of this study

- Network meta-analysis together with sensitivity analysis, contradiction analysis, and publication bias analysis will evaluate the efficacies of multiple anti-diabetic drugs.
- This study will provide evidence for clinical decision-makers to formulate better treatment of type 2 diabetes.
- This study is inherently retrospective and based on the published RCTs only.

## INTRODUCTION

Glycemic control would prevent microvascular and macrovascular complications of type 2 diabetes patients [1-2]. Several categories of oral anti-diabetic drugs including biguanides, thiazolidinediones, sulfonylureas, meglitinides, DPP-4 inhibitors and alpha-glucosidase inhibitors are available for monotherapy of type 2 diabetes. Efficacies of these drugs should be monitored for post-marketing evaluation and referred for updates of clinical guidelines. Randomized control trials (RCTs) and their meta-analyses are used in testing the efficacies of different treatments [3]. However, head-to-head RCTs do not cover all direct comparisons between drugs. Network meta-analysis, also known as mixed treatment comparison, was developed to incorporate direct and indirect evidence from RCTs [3].

Although the National Institute for Health and Care Excellence (NICE) guideline [4] is a popular clinical guideline for diabetes care, there are still gaps to provide the necessary evidence of the glycemic control efficacy of oral anti-diabetic drugs for updating the guideline. Firstly, the evidence of the oral anti-diabetic drugs efficacies was mainly based on head-to-head RCTs and their meta-analyses. Secondly, efficacy ranking of the oral anti-diabetic drugs was still unknown from the guideline due to the lack of comprehensive multiple comparisons among these drugs. Network meta-analyses had been used in comparing the efficacies of oral anti-diabetic drugs [5-7]. A network meta-analysis published in 2011 aimed to compare the efficacies of anti-diabetic drugs added to metformin [5]. Others published in 2012 and 2014 aimed to compare the efficacies of anti-diabetic drugs adding to metformin [3-4]. While these studies compared the drug combination efficacy of different classes, the monotherapy efficacy of individual drug is not been compared in network meta-analysis. Thirdly, robustness of multiple comparisons is still needed to be evaluated. Therefore, network meta-analysis on the monotherapy efficacies of oral anti-diabetic drugs by incorporating direct and indirect evidence based on randomized controlled trials (RCT) is necessary [8].

Twelve popular drugs, including metformin, pioglitazone, rosiglitazone, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin and acarbose, were selected from six oral anti-diabetic drug categories reported in the review [9] from the Agency for Healthcare Research and Quality. This study conducted a Bayesian network meta-analysis to compare the glycemic control efficacy of the selected anti-diabetic drugs.

## OBJECTIVES

The objective of this study is to compare efficacies of popular anti-diabetic drugs by Bayesian network meta-analysis on RCTs.

## METHODS AND ANALYSIS

### Design

Systematic review and Bayesian network meta-analysis.

### Information sources

Clinical trial reports will be searched from PubMed and Cochrane Library.

### Search strategies

Drug names, synonyms of type 2 diabetes (e.g. type 2 diabetes, type II diabetes and non-insulin-dependent diabetes) and “random\*” will be used as keywords to search titles or abstracts for eligible RCTs from major databases including PubMed, Cochrane Library, ScienceDirect, and EMBASE. For example, the following search strategy will be used in searching PubMed:

1. metformin
2. type 2 diabetes
3. random\*
4. 1 in title or abstract
5. 2 in title or abstract
6. 3 in title or abstract
7. 4 and 5 and 6

### Eligibility criteria

The retrieved reports will be screened according to the checklist of eligibility (Appendix 1) and the eligibility criteria shown below including participants, interventions, controls, types of study, and other criteria.

1  
2  
3 ▶ Participants

4  
5 Inclusion: the participants must be adults aged at least 18 suffering from and requiring treatment  
6  
7 for type 2 diabetes. Exclusion: the participants suffering from other diabetes disease conditions or  
8  
9 aged less than 18.

10  
11 ▶ Interventions

12  
13 Inclusion: any RCT that evaluates the efficacy of these twelve drugs. Exclusion: any RCT that  
14  
15 evaluates other drugs or combined treatments of multiple drugs or placebo.

16  
17 ▶ Controls

18  
19 Inclusion: any RCT that evaluates the efficacy of these twelve drugs other than the drug of  
20  
21 intervention or placebo. Exclusion: any RCT that evaluates other drugs or combined treatments of  
22  
23 multiple drugs.

24  
25 ▶ Types of study

26  
27 Inclusion: only RCTs will be included. Exclusion: Observational cohort and case-control studies,  
28  
29 case reports, experimental studies and reviews will be excluded.

30  
31 ▶ Other criteria

32  
33 Other inclusion criteria: the RCTs must report complete efficacy data of glycosylated hemoglobin  
34  
35 (HbA1c) or fasting blood-glucose (FPG) of each treatment. Follow-up periods or durations in  
36  
37 RCTs are at least 4 weeks. Other exclusion criteria are (a) duplicated or redundant studies, and (b)  
38  
39 combined treatments with multiple drugs.

40  
41 **Study selection**

42  
43 Reviewers will screen all titles or abstracts or full texts for database records independently  
44  
45 according to the eligibility criteria. Disagreements between reviewers will be resolved by  
46  
47 consensus. Selection process of relevant studies retrieved from databases will be shown in a  
48  
49 PRISMA-compliant [10] flowchart (Figure 1).

50  
51  
52 **Data extraction and quality assessment**

53  
54 Data of the study characteristics and the clinical outcome measures will be extracted. The data  
55  
56 extracted from the RCTs are: (a) authors; (b) publication year; (c) sample sizes; (d) interventions  
57  
58 of both arms; (e) dosages of both arms; (f) treatment outcome measures including glycosylated  
59  
60

1  
2  
3 hemoglobin (HbA1c) and fasting blood-glucose (FPG). The data will be standardized (Table 1).  
4  
5 The quality of eligible studies will be evaluated according to the Cochrane Collaboration's risk of  
6  
7 bias tool for assessing risk of bias (Table 2) [11]. Radar chart (or star chart) [12] will be used to  
8  
9 summary the results.

### 10 11 12 13 **Outcome measures**

14 Outcome measures of anti-diabetic efficacy include mean changes of HbA1c (primary outcome)  
15  
16 and FPG (secondary outcome) from baseline and their corresponding variation.

### 17 18 19 20 21 **Statistical analysis**

22 Pairwise meta-analysis of the included RCTs with random effect model [13-14] due to the  
23  
24 expected heterogeneity will be conducted. Mean difference (MD) will be used to synthesis the  
25  
26 continuous outcome data: mean changes from baseline of the HbA1c (%) and FPG (mol/L) in both  
27  
28 arms.  $I^2$  was used to estimate the heterogeneity [15]. Networks will be generated to visualize the  
29  
30 results of pairwise meta-analysis and the current evidence from the included RCTs.

31  
32 Network meta-analysis (NMA) based on the Bayesian hierarchical model [3] will be  
33  
34 performed to compare the efficacy of selected drugs. Placebo will be used as common comparison  
35  
36 [16] in NMA. Relative MD to the placebo will be output to assess the efficacy. The probability of  
37  
38 each drug being ranked in each position based on HbA1c will be computed [17]. Kendall's test  
39  
40 will be used to test the correlation between the relative MD and the ranking position.

41  
42 Sensitivity analysis based on the sample size of the RCTs will be conducted when RCTs with  
43  
44 sample size less than 50 are excluded. Begg's test [18] and Egger's test [19] will be used to  
45  
46 evaluate the publication bias. Agreement will be computed to assess the consistency between  
47  
48 pairwise and network meta-analyses.

49  
50 R software [20] will be used to implement the analysis workflow. Package "metafor" [21]  
51  
52 will be used to conduct pairwise meta-analysis. Package "igraph" [22] will be used to visualize the  
53  
54 networks. Package "fmsb" [23] will be used to visualize the results of risk of bias assessment.  
55  
56 Package "GeMTC" [24], "R2WinBUGS" [25] in R and WinBUGS [26] will be used to conducted  
57  
58 network meta-analysis. Package "ggplot2" [27] will be used to visualize the distribution of  
59  
60 ranking probability distribution. P Values lower than 0.05 will be considered statistically



1  
2  
3 significant.  
4  
5  
6

## 7 **ETHICS AND DISSEMINATION**

### 8 **Ethical issues**

9  
10 No ethical approval is required because this study include no confidential personal data and  
11 interventions with the patients.  
12  
13

### 14 **Publication plan**

15  
16 This protocol has been registered (Registration number: CRD42014010567) with the PROSPERO  
17 (International Prospective Register of Systematic Reviews) [28]. The procedures of this systematic  
18 review and network meta-analysis will be conducted in accordance with the PRISMA-compliant  
19 guideline. Details of this systematic review and network meta-analysis will be submitted to one of  
20 the BMJ journal.  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Contributions**

31  
32 SL conceived the study. SL and YL designed the study. YL and YJ tested the feasibility of the  
33 study. YJ, YL, and SL wrote the protocol and approved the final manuscript.  
34  
35  
36  
37  
38  
39

### 40 **Funding**

41  
42 The study is part of the “Open systematic reviewing of clinical trials” project supported by a  
43 research grant (MYRG190-Y3-L3-ICMS11-LSW) received from the University of Macau.  
44  
45  
46  
47

### 48 **Competing interests**

49  
50 None declared.  
51  
52  
53  
54

### 55 **Provenance and peer review**

56  
57 Not commissioned; external peer review.  
58  
59  
60

## Table Legends

Table 1. Summary of the included RCTs.

Table 2. RCT quality assessment with the Cochrane Collaboration's risk of bias tool.

## References

- 1 Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–89.
- 2 Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. *JAMA* 1999;281:2005–12.
- 3 Lu G, Ades a E. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med* 2004;23:3105–24.
- 4 National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update) (partially updated by CG87). Royal College of Physicians 2008; National Institute for Health and Clinical Excellence: NICE guidelines CG66.
- 5 Liu S, Tu Y, Chien M, et al. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. *Diabetes Obes Metab* 2012;14:810–20.
- 6 Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. *Diabetes Obes Metab* Published Online First: 14 November 2013.
- 7 Gross JL, Kramer CK, Leitão CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. *Ann Intern Med* 2011;154:672–9.
- 8 Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. *Value Health* 2008;11:956–64.
- 9 Bennett W, Wilson L, Bolen S. Oral diabetes medications for adults with type 2 diabetes: an update. Agency for Healthcare Research and Quality. 2011;1–320.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 10 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:1–6.
- 11 Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- 12 Chambers JM, Cleveland WS, Tukey PA, et al. *Graphical Methods for Data Analysis*. Wadsworth International Group, Duxbury Press, 1983.
- 13 Viechtbauer W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model. *J Educ Behav Stat* 2005;30:261–93.
- 14 Hedges LV, Vevea, JL. Fixed-and random-effects models in meta-analysis. *Psychol Methods* 1998; 3:486-504.
- 15 Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
- 16 Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. *Value Health* 2011;14:417–28.
- 17 Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet* 2009;373:746–58.
- 18 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088–101.
- 19 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315:629–34.
- 20 R Development Core Team. *R: a language and environment for statistical computing*. Reference index version 2.12.0. R Foundation for Statistical Computing, Vienna, Austria. 2008.
- 21 Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw* 2010;36:1–48.
- 22 Csardi G, Nepusz T. The igraph software package for complex network research. *Inter J, Complex Systems* 2006; 1695.
- 23 Nakazawa M. Functions for medical statistics book with some demographic data. R package Version 0.4.5, 2014.

- 1  
2  
3 24 Van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. *Res Synth*  
4 *Methods* 2012;3:285–99.  
5  
6  
7 25 Sturtz S, Ligges U, Gelman A. A Package for Running WinBUGS from R. *J Stat Softw*  
8 2005;12:1–16.  
9  
10 26 Lunn DJ, Thomas A, Best N, et al. WinBUGS - a Bayesian modelling framework: concepts,  
11 structure, and extensibility. *Stat Comput* 2000;10:325–37.  
12  
13  
14 27 Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer, 2009.  
15  
16 28 Jia Y, Lao Y, Leung S. Glycemic control efficacy of oral anti-diabetic drugs in treating type 2  
17 diabetes: a protocol for network meta-analysis. *PROSPERO* 2014; CRD42014010567.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Summary of the included RCTs.

Study	Sample size	Treatment duration	Drug 1 dosage	Drug 2 dosage	Drug 3 dosage	HbA1c	FPG
RCT 1							
RCT 2							
RCT 3							
RCT 4							
RCT 5							
...							


For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 2. RCT quality assessment according to the Cochrane Collaboration's risk of bias tool.

	RCT 1	RCT 2	RCT 3	RCT 4	RCT 5	...
Random sequence generation						
Allocation concealment						
Blinding of participants and personnel						
Blinding of outcome assessment						
Incomplete outcome data						
Selective reporting						
Other sources of bias						

Each item of included RCT will be evaluated at low risk, unclear risk and high risk of bias based on the Cochrane Collaboration's risk of bias tool [11].



Flowchart of study selection  
145x142mm (300 x 300 DPI)

Preprint

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Appendix 1: Checklist of eligibility.

The study will be excluded when there is a negative (“No”) answer to any of following questions:

1. Is the study a randomized controlled trial?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

2. Are the participants suffering from type 2 diabetes?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

3. Is the intervention under treatment with any one of selected twelve anti-diabetic drugs?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

4. Is the control under treatment with any one of selected twelve anti-diabetic drugs other than the drug of intervention or placebo?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

5. Do the outcome measures include at least one of glycosylated hemoglobin or fasting blood-glucose for each treatment?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

6. Is the follow-up periods at least four weeks?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

7. Is the study a non-duplicated and non-redundant publication?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_



# BMJ Open

## Glycemic control efficacy of oral anti-diabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006139.R1
Article Type:	Protocol
Date Submitted by the Author:	16-Oct-2014
Complete List of Authors:	Leung, Siu-wai; University of Edinburgh, School of Informatics; University of Macau, Institute of Chinese Medical Sciences Jia, Yongliang; University of Macau, Institute of Chinese Medical Sciences Lao, Yaoguang; University of Macau, Institute of Chinese Medical Sciences
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Evidence based practice, Health informatics, Pharmacology and therapeutics
Keywords:	Health informatics < BIOTECHNOLOGY & BIOINFORMATICS, General diabetes < DIABETES & ENDOCRINOLOGY, Diabetes & endocrinology < INTERNAL MEDICINE

SCHOLARONE™  
Manuscripts

Glycemic control efficacy of oral anti-diabetic drugs in treating type 2 diabetes:  
a protocol for network meta-analysis

Yongliang Jia<sup>1,#</sup>, Yaoguang Lao<sup>1,#</sup>, Siu-wai Leung<sup>1,2\*</sup>

Affiliations:

1. State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China
2. School of Informatics, University of Edinburgh, Edinburgh EH8 9AB, United Kingdom

Email addresses:

YJ: [gentrany@gmail.com](mailto:gentrany@gmail.com)

YL: [yaoguangleo@163.com](mailto:yaoguangleo@163.com)

SL: [swleung@umac.mo](mailto:swleung@umac.mo)

Phone: +853-8822-8524

\*Corresponding author

# Co-first authors

Keywords: protocol; type 2 diabetes; glycemic control; randomized controlled trials; network meta-analysis.

Word count: 1580

**Abstract****Introduction:**

The past studies of network meta-analysis focused on evaluating drug combinations in treating type 2 diabetes, not evaluating anti-diabetic drugs in monotherapy. Clinical guidelines (e.g. NICE clinical guidelines 66 and 87) were only based on the findings of individual clinical trials and pairwise meta-analysis in evaluating monotherapy. This study aims to fill this gap of research by conducting a Bayesian network meta-analysis to compare major anti-diabetic drugs, including metformin, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin, and SGLT-2 inhibitors.

**Methods and analyses:**

Randomized controlled trials (RCT) on the drug therapy of type 2 diabetes with outcome measures including glycosylated hemoglobin (HbA1c) or fasting blood-glucose (FPG) will be included. The quality of included RTCs will be evaluated according to the Cochrane Collaboration's risk of bias tool. Traditional pairwise meta-analysis and Bayesian network meta-analysis will be conducted to compare the efficacies of anti-diabetic drugs. Sensitivity analysis on the sample size of RCTs, meta-regression analysis on the follow-up periods, dosages, and baselines of outcome measure, contradiction analysis between pairwise and network meta-analyses, and publication bias analysis will be performed.

**Ethics and dissemination:**

Ethical approval is not required because this study includes no confidential personal data and interventions on the patients. Pairwise and network meta-analyses are based on the published RCT reports of eligible drugs in treating type 2 diabetes. The results of this study will be disseminated by a peer-reviewed publication.

**Protocol registration:**

PROSPERO CRD42014010567.

## ARTICLE SUMMARY

## Strengths and limitations of this study

- Network meta-analysis together with sensitivity analysis, contradiction analysis, and publication bias analysis will evaluate the efficacies of multiple anti-diabetic drugs.
- This study will provide evidence for clinical decision-makers to formulate better treatment of type 2 diabetes.
- This study is inherently retrospective and based on the published RCTs only.

## INTRODUCTION

Glycemic control would prevent microvascular and macrovascular complications of type 2 diabetes [1-2]. Several categories of oral anti-diabetic drugs including biguanides, thiazolidinediones, sulfonylureas, meglitinides, DPP-4 inhibitors and alpha-glucosidase inhibitors are available for monotherapy of type 2 diabetes. Efficacies of these drugs should be monitored for post-marketing evaluation and for updates of clinical guidelines. However, the latest National Institute for Health and Care Excellence (NICE) guidelines [3-4] for treating type 2 diabetes did only include the randomized control trials (RCTs) and their meta-analyses published before 2010.

Even if the clinical guidelines were up to date, there are still gaps to be filled among the current pieces of evidence for the glycemic control efficacy of oral anti-diabetic drugs. Firstly, the current evidence for the oral anti-diabetic drugs efficacies was only limited number of head-to-head RCTs and meta-analyses, including the most comprehensive study by the Agency for Healthcare Research and Quality [5], that cannot cover all possible comparisons among individual drugs. Under this situation, network meta-analysis that can integrate the evidence from direct and indirect comparisons [6] would be applicable. Secondly, efficacy ranking of the oral anti-diabetic drugs was still unknown. The drug recommendation by the clinical guidelines was not based on comprehensive and systematic studies for comparing multiple drugs. This gap also suggests an imminent need for network meta-analysis that can rank all evaluated interventions [7].

While network meta-analysis was used in comparing the efficacies of oral anti-diabetic drugs, the available network meta-analyses [8-10] evaluated only treatments combined with metformin. The monotherapy efficacies of individual drugs have not been studied by network meta-analysis.

This study conducted a Bayesian network meta-analysis [11] to compare the glycemic control efficacy of popular oral anti-diabetic drugs, including metformin, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin, and SGLT-2 inhibitors.

## OBJECTIVES

The objective of this study is to compare efficacies of popular anti-diabetic drugs by Bayesian network meta-analysis on RCTs.

## METHODS AND ANALYSIS

## Design

Systematic review and Bayesian network meta-analysis.

## Information sources

Clinical trial reports will be searched from PubMed and Cochrane Library.

## Search strategies

Drug names, synonyms of type 2 diabetes (e.g. type 2 diabetes, type II diabetes and non-insulin-dependent diabetes) and “random\*” will be used as keywords to search titles or abstracts for eligible RCTs from major databases including PubMed, Cochrane Library, ScienceDirect, and EMBASE as well as FDA medical reviews, clinicaltrials.gov website. The search is scheduled between August and October in 2014. For example, the following search strategy will be used in searching PubMed:

1. metformin
2. type 2 diabetes
3. random\*
4. 1 in title or abstract
5. 2 in title or abstract
6. 3 in title or abstract
7. 4 and 5 and 6

## Eligibility criteria

The retrieved reports will be screened according to the checklist of eligibility (Appendix 1) and the eligibility criteria shown below including participants, interventions, controls, types of study, and other criteria.

### ► Participants

Inclusion: the participants must be adults aged at least 18 suffering from and requiring treatment for type 2 diabetes. Exclusion: the participants suffering from other diabetes disease conditions or aged less than 18.

### ► Interventions

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Inclusion: any RCT that evaluates the efficacy of these drugs. Exclusion: any RCT that evaluates other drugs or combined treatments of multiple drugs or placebo.

► Controls

Inclusion: any RCT that evaluates the efficacy of these drugs other than the drug of intervention or placebo. Exclusion: any RCT that evaluates other drugs or combined treatments of multiple drugs.

► Types of study

Inclusion: only RCTs will be included. Exclusion: Observational cohort and case-control studies, case reports, experimental studies and reviews will be excluded.

► Other criteria

Other inclusion criteria: the RCTs must report complete efficacy data of glycosylated hemoglobin (HbA1c) or fasting blood-glucose (FPG) of each treatment. Follow-up periods or durations in RCTs are at least 4 weeks. Other exclusion criteria are (a) duplicated or redundant studies, and (b) combined treatments with multiple drugs.

### Study selection

Reviewers will screen all titles or abstracts or full texts for database records independently according to the eligibility criteria. Disagreements between reviewers will be resolved by consensus. Selection process of relevant studies retrieved from databases will be shown in a PRISMA-compliant [12] flowchart (Figure 1).

### Data extraction and quality assessment

Data of the study characteristics and the clinical outcome measures will be extracted. The data extracted from the RCTs are: (a) authors; (b) publication year; (c) baseline of outcome measures; (d) sample sizes; (e) interventions of both arms; (f) dosages of both arms; (g) treatment outcome measures including glycosylated hemoglobin (HbA1c) and fasting blood-glucose (FPG). The data will be standardized (Table 1). The quality of eligible studies will be evaluated according to the Cochrane Collaboration's risk of bias tool for assessing risk of bias (Table 2) [13]. Radar chart (or star chart) [14] will be used to summary the results.

### Outcome measures

1  
2  
3 Outcome measures of anti-diabetic efficacy include mean changes of HbA1c (primary outcome)  
4 and FPG (secondary outcome) from baseline and their corresponding variation.  
5  
6  
7  
8

### 9 **Statistical analysis**

10 Pairwise meta-analysis of the included RCTs with random effect model [15-16] due to the  
11 expected heterogeneity will be conducted. Mean difference (MD) will be used to synthesis the  
12 continuous outcome data: mean changes from baseline of the HbA1c (%) and FPG (mol/L) in both  
13 arms.  $I^2$  was used to estimate the heterogeneity [17]. Networks will be generated to visualize the  
14 results of pairwise meta-analysis and the current evidence from the included RCTs.  
15  
16  
17  
18  
19

20 Network meta-analysis (NMA) based on the Bayesian hierarchical model [8] will be  
21 performed to compare the efficacy of selected drugs. Placebo will be used as common comparison  
22 [18] in NMA. Relative MD to the placebo will be output to assess the efficacy. The probability of  
23 each drug being ranked in each position based on HbA1c will be computed [19]. Kendall's test  
24 will be used to test the correlation between the relative MD and the ranking position.  
25  
26  
27  
28  
29

30 Sensitivity analysis based on the sample size of the RCTs will be conducted when RCTs with  
31 sample size less than 50 are excluded. Sensitivity analysis will also be conducted on different  
32 baselines. Meta-regression analyses will be conducted on the different follow-up periods and  
33 dosages for drugs of the included RCTs. Begg's test [20] and Egger's test [21] will be used to  
34 evaluate the publication bias. Agreement will be computed to assess the consistency between  
35 pairwise and network meta-analyses.  
36  
37  
38  
39  
40

41 R software [22] will be used to implement the analysis workflow. Package "metafor" [23]  
42 will be used to conduct pairwise meta-analysis. Package "igraph" [24] will be used to visualize the  
43 networks. Package "fmsb" [25] will be used to visualize the results of risk of bias assessment.  
44 Package "GeMTC" [26], "R2WinBUGS" [27] in R and WinBUGS [28] will be used to conducted  
45 network meta-analysis. Package "ggplot2" [29] will be used to visualize the distribution of  
46 ranking probability distribution. P values lower than 0.05 will be considered statistically  
47 significant.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## ETHICS AND DISSEMINATION

### Ethical issues

No ethical approval is required because this study include no confidential personal data and interventions with the patients.

### Publication plan

This protocol has been registered (Registration number: CRD42014010567) with the PROSPERO (International Prospective Register of Systematic Reviews) [30]. The procedures of this systematic review and network meta-analysis will be conducted in accordance with the PRISMA-compliant guideline. The results of this systematic review and network meta-analysis will be submitted to a peer-reviewed journal for publication.

### Contributions

SL conceived the study. SL, YL, and YJ designed the protocol. YL and YJ tested the feasibility of the study. YJ, YL, and SL wrote the protocol and approved the final manuscript.

### Funding

The study is part of the “Open systematic reviewing of clinical trials” project supported by a research grant (MYRG190-Y3-L3-ICMS11-LSW) received from the University of Macau.

### Competing interests

None declared.

### Provenance and peer review

Not commissioned; external peer review.

**Table legends**

Table 1. Summary of the included RCTs.

Table 2. RCT quality assessment with the Cochrane Collaboration's risk of bias tool.

**References**

- 1 Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–89.
- 2 Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. *JAMA* 1999;281:2005–12.
- 3 National Institute for Health and Clinical Excellence. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update) (partially updated by CG87). NICE clinical guideline 66.
- 4 National Institute for Health and Clinical Excellence. Type 2 diabetes: The management of type 2 diabetes. NICE clinical guideline 87.
- 5 Bennett W, Wilson L, Bolen S. Oral diabetes medications for adults with type 2 diabetes: an update. Agency for Healthcare Research and Quality. 2011;1–320.
- 6 Lu G, Ades a E. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med* 2004;23:3105–24.
- 7 Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011; 64:163–171.
- 8 Gross JL, Kramer CK, Leitão CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. *Ann Intern Med* 2011;154:672–9.
- 9 Liu S, Tu Y, Chien M, et al. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. *Diabetes Obes Metab* 2012;14:810–20.
- 10 Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. *Diabetes Obes Metab* Published Online First: 14 November 2013.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 11 Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. *Value Health* 2008;11:956–64.
- 11 Bennett W, Wilson L, Bolen S. Oral diabetes medications for adults with type 2 diabetes: an update. *Agency for Healthcare Research and Quality*. 2011;1–320.
- 12 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:1–6.
- 13 Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- 14 Chambers JM, Cleveland WS, Tukey PA, et al. *Graphical Methods for Data Analysis*. Wadsworth International Group, Duxbury Press, 1983.
- 15 Viechtbauer W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model. *J Educ Behav Stat* 2005;30:261–93.
- 16 Hedges LV, Vevea, JL. Fixed-and random-effects models in meta-analysis. *Psychol Methods* 1998; 3:486-504.
- 17 Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
- 18 Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. *Value Health* 2011;14:417–28.
- 19 Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet* 2009;373:746–58.
- 20 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088–101.
- 21 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315:629–34.
- 22 R Development Core Team. *R: a language and environment for statistical computing*. Reference index version 2.12.0. R Foundation for Statistical Computing, Vienna, Austria. 2008.
- 23 Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw* 2010;36:1–48.

- 1  
2  
3 24 Csardi G, Nepusz T. The igraph software package for complex network research. *Inter J, Complex Systems* 2006; 1695.
- 4  
5  
6  
7 25 Nakazawa M. Functions for medical statistics book with some demographic data. R package Version 0.4.5, 2014.
- 8  
9  
10 26 Van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. *Res Synth Methods* 2012;3:285–99.
- 11  
12  
13  
14 27 Sturtz S, Ligges U, Gelman A. A Package for Running WinBUGS from R. *J Stat Softw* 2005;12:1–16.
- 15  
16  
17 28 Lunn DJ, Thomas A, Best N, et al. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. *Stat Comput* 2000;10:325–37.
- 18  
19  
20  
21 29 Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer, 2009.
- 22  
23  
24 30 Jia Y, Lao Y, Leung S. Glycemic control efficacy of oral anti-diabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis. *PROSPERO* 2014; CRD42014010567.
- 25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Summary of the included RCTs.

Study	Baseline	Sample size	Treatment duration	Drug 1 dosage	Drug 2 dosage	Drug 3 dosage	HbA1c	FPG
RCT 1								
RCT 2								
RCT 3								
RCT 4								
RCT 5								
...								

For peer review only

Table 2. RCT quality assessment according to the Cochrane Collaboration's risk of bias tool.

	RCT 1	RCT 2	RCT 3	RCT 4	RCT 5	...
Random sequence generation						
Allocation concealment						
Blinding of participants and personnel						
Blinding of outcome assessment						
Incomplete outcome data						
Selective reporting						
Other sources of bias						

Each item of included RCT will be evaluated at low risk, unclear risk and high risk of bias based on the Cochrane Collaboration's risk of bias tool [13].

Glycemic control efficacy of oral anti-diabetic drugs in treating type 2 diabetes:  
a protocol for network meta-analysis

Yongliang Jia<sup>1, #</sup> Yaoguang Lao<sup>1, #</sup> Siu-wai Leung<sup>1, 2\*</sup>

Affiliations:

1. State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China
2. School of Informatics, University of Edinburgh, Edinburgh EH8 9AB, United Kingdom

Email addresses:

YJ: [gentrany@gmail.com](mailto:gentrany@gmail.com)

YL: [yaoguangleo@163.com](mailto:yaoguangleo@163.com)

SL: [swleung@umac.mo](mailto:swleung@umac.mo)

Phone: +853-~~83978822~~-8524

\*Corresponding author

~~# Co-first authors~~

Keywords: protocol; type 2 diabetes; glycemic control; randomized controlled trials; network meta-analysis.

Word count: ~~16191580~~

## ARTICLE SUMMARY

**Article focus**

~~■ This is a protocol of systematic review and network meta-analysis of randomized controlled trials on metformin, pioglitazone, rosiglitazone, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin and acarbose in treating type 2 diabetes.~~

**Key messages**

- ~~■ Included drugs will be evaluated by pairwise and a Bayesian network meta-analysis.~~
- ~~■ Sensitivity analysis, contradiction analysis, and publication bias analysis will be conducted to compare the efficacy of drugs with glycosylated hemoglobin and fasting blood glucose outcome measures.~~

**Strengths and limitations of this study**

- Network meta-analysis together with sensitivity analysis, contradiction analysis, and publication bias analysis will evaluate the efficacies of multiple anti-diabetic drugs.
- This study will provide evidence for clinical decision-makers to formulate better treatment of type 2 diabetes.
- This study is inherently retrospective and based on the published RCTs only.



---

## Abstract

### Introduction:

~~There were three~~ The past studies of network meta-analyses analysis focused on the efficacy of anti-diabetic evaluating drug combinations in treating type 2 diabetes. ~~No network meta-analytic study has been published, not evaluating anti-diabetic drugs in medical journal to evaluate the efficacies of~~ monotherapy. Current clinical Clinical guidelines (e.g. NICE clinical guidelines 66 and 87) ~~are~~ were only based on the findings of ~~limited~~ individual clinical trials and pairwise meta-analysis. in evaluating monotherapy. This study aims to fill this gap of research by conducting a Bayesian network meta-analysis to compare ~~twelve~~ major anti-diabetic drugs, including metformin, ~~pioglitazone, rosiglitazone,~~ glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin, and ~~acarbose~~ SGLT-2 inhibitors.

### Methods and analyses:

Randomized controlled trials (RCT) on the drug therapy of type 2 diabetes with outcome measures including glycosylated hemoglobin (HbA1c) or fasting blood-glucose (FPG) will be included. The quality of ~~inlueed~~ included RTCs will be evaluated according to the Cochrane Collaboration's risk of bias tool. ~~Overall effect sizes will be represented as mean differences with 95% credible intervals (CrI) for continuous outcome data. Pairwise~~ Traditional pairwise meta-analysis ~~in R software~~ and Bayesian network meta-analysis ~~in R and WinBUGS~~ will be conducted to compare the efficacies of ~~these~~ anti-diabetic drugs. Sensitivity analysis on the sample size of RCTs, meta-regression analysis on the follow-up periods, dosages, and baselines of outcome measure, contradiction analysis between ~~pair~~ pairwise and network meta-analyses, and publication bias analysis will be performed.

### Ethics and dissemination:

Ethical approval is not required because this study ~~include~~ includes no confidential personal data and interventions on the patients. ~~Network~~ Pairwise and network meta-analysis ~~is~~ analyses are based on the published RCT reports of eligible drugs in treating type 2 diabetes. The results of this study will be disseminated by ~~an open access and~~ a peer-reviewed publication.

### Protocol registration:

PROSPERO CRD42014010567.

## INTRODUCTION

Glycemic control would prevent microvascular and macrovascular complications of type 2 diabetes ~~patients~~ [1-2]. Several categories of oral anti-diabetic drugs including biguanides, thiazolidinediones, sulfonylureas, meglitinides, DPP-4 inhibitors and alpha-glucosidase inhibitors are available for monotherapy of type 2 diabetes. Efficacies of these drugs should be monitored for post-marketing evaluation and ~~referred~~ for updates of clinical guidelines. ~~Randomized~~ However, the latest National Institute for Health and Care Excellence (NICE) guidelines [3-4] for treating type 2 diabetes did only include the randomized control trials (RCTs) and their meta-analyses ~~are used in testing the efficacies of different treatments [3]. However, head-to-head RCTs do not cover all direct comparisons between drugs. Network meta-analysis, also known as mixed treatment comparison, was developed to incorporate direct and indirect evidence from RCTs [3], published before 2010.~~

~~Although~~ Even if the National Institute for Health and Care Excellence (NICE) guideline [4] ~~is a popular clinical guideline for diabetes care guidelines were up to date,~~ there are still gaps to ~~provide be filled among the necessary current pieces of evidence~~ ~~effor~~ the glycemic control efficacy of oral anti-diabetic drugs ~~for updating the guideline.~~ Firstly, the current ~~effor~~ evidence ~~effor~~ the oral anti-diabetic drugs efficacies was ~~mainly based on only limited number of~~ head-to-head RCTs and ~~their~~ meta-analyses, including the most comprehensive study by the Agency for Healthcare Research and Quality [5], that cannot cover all possible comparisons among individual drugs. Under this situation, network meta-analysis that can integrate the evidence from direct and indirect comparisons [6] would be applicable. Secondly, efficacy ranking of the oral anti-diabetic drugs was still unknown ~~from.~~ The drug recommendation by the guideline due to the lack ~~of~~ clinical guidelines was not based on comprehensive and systematic studies for comparing multiple ~~comparisons among these drugs. Network meta-analyses had been~~ drugs. This gap also suggests an imminent need for network meta-analysis that can rank all evaluated interventions [7].

While network meta-analysis was used in comparing the efficacies of oral anti-diabetic drugs ~~[5-7]. A network meta-analysis published in 2011 aimed to compare the~~ the available network meta-analyses [8-10] evaluated only treatments combined with metformin. The monotherapy efficacies of anti-diabetic drugs added to metformin [5]. Others published in 2012 and 2014 aimed to compare the efficacies of anti-diabetic drugs adding to metformin [3-4]. While these studies

~~compared the drug combination efficacy of different classes, the monotherapy efficacy of individual drug is not been compared in network meta-analysis. Thirdly, robustness of multiple comparisons is still needed to be evaluated. Therefore, network meta-analysis on the monotherapy efficacies of individual drugs have not been studied by network meta-analysis.~~

~~This study conducted a Bayesian network meta-analysis [11] to compare the glyceemic control efficacy of popular oral anti-diabetic drugs by incorporating direct and indirect evidence based on randomized controlled trials (RCT) is necessary [8].~~

~~Twelve popular drugs, including metformin, pioglitazone, rosiglitazone, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin, and acarbose, were selected from six oral anti diabetic drug categories reported in the review [9] from the Agency for Healthcare Research and Quality. This study conducted a Bayesian network meta-analysis to compare the glyceemic control efficacy of the selected anti-diabetic drugs. SGLT-2 inhibitors.~~

## OBJECTIVES

The objective of this study is to compare efficacies of popular anti-diabetic drugs by Bayesian network meta-analysis on RCTs.

## METHODS AND ANALYSIS

### Design

Systematic review and Bayesian network meta-analysis.

### Information sources

Clinical trial reports will be searched from PubMed and Cochrane Library.

### Search strategies

Drug names, synonyms of type 2 diabetes (e.g. type 2 diabetes, type II diabetes and non-insulin-dependent diabetes) and “random\*” will be used as keywords to search titles or abstracts for eligible RCTs from major databases including PubMed, Cochrane Library, ScienceDirect, and EMBASE- as well as FDA medical reviews, clinicaltrials.gov website. The

search is scheduled between August and October in 2014. For example, the following search strategy will be used in searching PubMed:

1. metformin
2. type 2 diabetes
3. random\*
4. 1 in title or abstract
5. 2 in title or abstract
6. 3 in title or abstract
7. 4 and 5 and 6

### Eligibility criteria

The retrieved reports will be screened according to the checklist of eligibility (Appendix 1) and the eligibility criteria shown below including participants, interventions, controls, types of study, and other criteria.

#### ► Participants

Inclusion: the participants must be adults aged at least 18 suffering from and requiring treatment for type 2 diabetes. Exclusion: the participants suffering from other diabetes disease conditions or aged less than 18.

#### ► Interventions

Inclusion: any RCT that evaluates the efficacy of these ~~twelve~~ drugs. Exclusion: any RCT that evaluates other drugs or combined treatments of multiple drugs or placebo.

#### ► Controls

Inclusion: any RCT that evaluates the efficacy of these ~~twelve~~ drugs other than the drug of intervention or placebo. Exclusion: any RCT that evaluates other drugs or combined treatments of multiple drugs.

#### ► Types of study

Inclusion: only RCTs will be included. Exclusion: Observational cohort and case-control studies, case reports, experimental studies and reviews will be excluded.

#### ► Other criteria

Other inclusion criteria: the RCTs must report complete efficacy data of glycosylated hemoglobin

(HbA1c) or fasting blood-glucose (FPG) of each treatment. Follow-up periods or durations in RCTs are at least 4 weeks. Other exclusion criteria are (a) duplicated or redundant studies, and (b) combined treatments with multiple drugs.

### Study selection

Reviewers will screen all titles or abstracts or full texts for database records independently according to the eligibility criteria. Disagreements between reviewers will be resolved by consensus. Selection process of relevant studies retrieved from databases will be shown in a PRISMA-compliant [4012] flowchart (Figure 1).

### Data extraction and quality assessment

Data of the study characteristics and the clinical outcome measures will be extracted. The data extracted from the RCTs are: (a) authors; (b) publication year; (c) baseline of outcome measures; (d) sample sizes; (de) interventions of both arms; (ef) dosages of both arms; (fg) treatment outcome measures including glycosylated hemoglobin (HbA1c) and fasting blood-glucose (FPG). The data will be standardized (Table 1). The quality of eligible studies will be evaluated according to the Cochrane Collaboration's risk of bias tool for assessing risk of bias (Table 2) [4113]. Radar chart (or star chart) [4214] will be used to summary the results.

### Outcome measures

Outcome measures of anti-diabetic efficacy include mean changes of HbA1c (primary outcome) and FPG (secondary outcome) from baseline and their corresponding variation.

### Statistical analysis

Pairwise meta-analysis of the included RCTs with random effect model [43-4415-16] due to the expected heterogeneity will be conducted. Mean difference (MD) will be used to synthesis the continuous outcome data: mean changes from baseline of the HbA1c (%) and FPG (mol/L) in both arms.  $I^2$  was used to estimate the heterogeneity [4517]. Networks will be generated to visualize the results of pairwise meta-analysis and the current evidence from the included RCTs.

Network meta-analysis (NMA) based on the Bayesian hierarchical model [38] will be

performed to compare the efficacy of selected drugs. Placebo will be used as common comparison [4618] in NMA. Relative MD to the placebo will be output to assess the efficacy. The probability of each drug being ranked in each position based on HbA1c will be computed [4719]. Kendall's test will be used to test the correlation between the relative MD and the ranking position.

Sensitivity analysis based on the sample size of the RCTs will be conducted when RCTs with sample size less than 50 are excluded. Begg's test [18] and Egger's test [19] Sensitivity analysis will also be conducted on different baselines. Meta-regression analyses will be conducted on the different follow-up periods and dosages for drugs of the included RCTs. Begg's test [20] and Egger's test [21] will be used to evaluate the publication bias. Agreement will be computed to assess the consistency between pairwise and network meta-analyses.

R software [2022] will be used to implement the analysis workflow. Package "metafor" [2123] will be used to conduct pairwise meta-analysis. Package "igraph" [2224] will be used to visualize the networks. Package "fmsb" [2325] will be used to visualize the results of risk of bias assessment. Package "GeMTC" [246], "R2WinBUGS" [2527] in R and WinBUGS [2628] will be used to conducted network meta-analysis. Package "ggplot2" [2729] will be used to visualize the distribution of ranking probability distribution. P Values values lower than 0.05 will be considered statistically significant.

## ETHICS AND DISSEMINATION

### Ethical issues

No ethical approval is required because this study include no confidential personal data and interventions with the patients.

### Publication plan

This protocol has been registered (Registration number: CRD42014010567) with the PROSPERO (International Prospective Register of Systematic Reviews) [2830]. The procedures of this systematic review and network meta-analysis will be conducted in accordance with the PRISMA-compliant guideline. Details The results of this systematic review and network

meta-analysis will be submitted to ~~one of the BMJ~~ [peer-reviewed journal for publication](#).

### Contributions

SL conceived the study. SL, [YL](#), and [Y+YJ](#) designed the [study-protocol](#). YL and YJ tested the feasibility of the study. YJ, YL, and SL wrote the protocol and approved the final manuscript.

### Funding

The study is part of the “Open systematic reviewing of clinical trials” project supported by a research grant (MYRG190-Y3-L3-ICMS11-LSW) received from the University of Macau.

### Competing interests

None declared.

### Provenance and peer review

Not commissioned; external peer review.

### Table ~~Legends~~[legends](#)

Table 1. Summary of the included RCTs.

Table 2. RCT quality assessment with the Cochrane Collaboration’s risk of bias tool.

### References

- 1 Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577–89.
- 2 Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. *JAMA* 1999;281:2005–12.

- ~~3-3~~ [National Institute for Health and Clinical Excellence. Lu G, Ades a E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105–24.](#)
- ~~4~~ [National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care \(update\) \(partially updated by CG87\). Royal College of Physicians 2008; National Institute for Health and Clinical Excellence: NICE guidelines CG66 NICE clinical guideline 66.](#)
- ~~5-4~~ [National Institute for Health and Clinical Excellence. Type 2 diabetes: The management of type 2 diabetes. NICE clinical guideline 87.](#)
- ~~5~~ [Bennett W, Wilson L, Bolen S. Oral diabetes medications for adults with type 2 diabetes: an update. Agency for Healthcare Research and Quality. 2011;1–320.](#)
- ~~6~~ [Lu G, Ades a E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105–24.](#)
- ~~7~~ [Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011; 64:163–171.](#)
- ~~8~~ [Gross JL, Kramer CK, Leitão CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011;154:672–9.](#)
- ~~9~~ Liu S, Tu Y, Chien M, et al. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012;14:810–20.
- ~~610~~ Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab Published Online First: 14 November 2013.
- ~~711~~ [Gross JL, Kramer CK, Leitão CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011;154:672–9.](#)
- ~~8~~ Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956–64.
- ~~911~~ [Bennett W, Wilson L, Bolen S. Oral diabetes medications for adults with type 2 diabetes: an update. Agency for Healthcare Research and Quality. 2011;1–320.](#)
- ~~12~~ [Bennett W, Wilson L, Bolen S. Oral diabetes medications for adults with type 2 diabetes: an update. Agency for Healthcare Research and Quality. 2011;1–320.](#)



- 1  
2  
3  
4  
5  
6 | ~~10~~ Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and  
7 meta-analyses: the PRISMA statement. PLoS Med 2009;6:1–6.  
8  
9 | ~~11~~ Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing  
10 risk of bias in randomised trials. BMJ 2011;343:d5928.  
11  
12 | ~~12~~ Chambers JM, Cleveland WS, Tukey PA, et al. Graphical Methods for Data Analysis.  
13 Wadsworth International Group, Duxbury Press, 1983.  
14  
15 | ~~13~~ Viechtbauer W. Bias and Efficiency of Meta-Analytic Variance Estimators in the  
16 Random-Effects Model. J Educ Behav Stat 2005;30:261–93.  
17  
18 | ~~14~~ Hedges LV, Vevea, JL. Fixed-and random-effects models in meta-analysis. Psychol Methods  
19 1998; 3:486-504.  
20  
21 | ~~15~~ Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ  
22 2003;327:557–60.  
23  
24 | ~~16~~ Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and  
25 network meta-analysis for health-care decision making: report of the ISPOR Task Force on  
26 Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417–  
27 28.  
28  
29 | ~~17~~ Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12  
30 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746–58.  
31  
32 | ~~18~~ Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.  
33 Biometrics 1994;50:1088–101.  
34  
35 | ~~19~~ Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,  
36 graphical test. BMJ. 1997;315:629–34.  
37  
38 | ~~20~~ R Development Core Team. R: a language and environment for statistical computing.  
39 Reference index version 2.12.0. R Foundation for Statistical Computing, Vienna, Austria.  
40 2008.  
41  
42 | ~~21~~ Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw  
43 2010;36:1–48.  
44  
45 | ~~22~~ Csardi G, Nepusz T. The igraph software package for complex network research. Inter J,  
46 Complex Systems 2006; 1695.  
47  
48 | ~~23~~ Nakazawa M. Functions for medical statistics book with some demographic data. R package  
49 Version 0.4.5, 2014.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 
- 1  
2  
3  
4  
5  
6 | [2426](#) Van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. *Res Synth*  
7 *Methods* 2012;3:285–99.  
8  
9 | [2527](#) Sturtz S, Ligges U, Gelman A. A Package for Running WinBUGS from R. *J Stat Softw*  
10 2005;12:1–16.  
11  
12 | [2628](#) Lunn DJ, Thomas A, Best N, et al. WinBUGS - a Bayesian modelling framework: concepts,  
13 structure, and extensibility. *Stat Comput* 2000;10:325–37.  
14  
15 | [2729](#) Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer, 2009.  
16  
17 | [2830](#) Jia Y, Lao Y, Leung S. Glycemic control efficacy of oral anti-diabetic drugs in treating type 2  
18 diabetes: a protocol for network meta-analysis. *PROSPERO* 2014; CRD42014010567.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Summary of the included RCTs.

Study	Baseline	Sample size	Treatment duration	Drug 1 dosage	Drug 2 dosage	Drug 3 dosage	HbA1c	FBG
RCT 1								
RCT 2								
RCT 3								
RCT 4								
RCT 5								
...								


Inserted Cells

For peer review only

Table 2. RCT quality assessment according to the Cochrane Collaboration's risk of bias tool.

	RCT 1	RCT 2	RCT 3	RCT 4	RCT 5	...
Random sequence generation						
Allocation concealment						
Blinding of participants and personnel						
Blinding of outcome assessment						
Incomplete outcome data						
Selective reporting						
Other sources of bias						

Each item of included RCT will be evaluated at low risk, unclear risk and high risk of bias based on the Cochrane Collaboration's risk of bias tool [44,45].



Flowchart of study selection  
145x142mm (300 x 300 DPI)

Preprint

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Appendix 1: Checklist of eligibility.

The study will be excluded when there is a negative (“No”) answer to any of following questions:

1. Is the study a randomized controlled trial?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

2. Are the participants suffering from type 2 diabetes?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

3. Is the intervention under treatment with any one of selected twelve anti-diabetic drugs?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

4. Is the control under treatment with any one of selected twelve anti-diabetic drugs other than the drug of intervention or placebo?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

5. Do the outcome measures include at least one of glycosylated hemoglobin or fasting blood-glucose for each treatment?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

6. Is the follow-up periods at least four weeks?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_

7. Is the study a non-duplicated and non-redundant publication?

Yes \_\_\_\_

No \_\_\_\_

Unclear \_\_\_\_